Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC with FOLFOX vs Sorafenib in TACE-resistant HCC
NCT05121571Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Started Apr 2016; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05121571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121571.